Newsfeeds Archive - Spark Newswire

4 minute read

Aurinia Pharmaceuticals Shareholder Urges Board Of Directors To Take Action To Enhance Shareholder Value; Outlines Concerns Regarding The Company’s Current Strategy And Board Composition And Offers Superior Paths To Improving Performance And Market Pen…

May 7, 9:18 AM

Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Performance and Market PenetrationLucien Selce, who owns approximately 2.2% of the outstanding

AUPH

4 minute read

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Avi Kapoor

February 15, 2:20 PM

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

AMWL

2 minute read

Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback

By Vandana Singh

February 15, 10:51 AM

Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated.

AUPH

10 minute read

Earnings

Earnings Scheduled For February 15, 2024

By Benzinga Insights

February 15, 6:17 AM

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

AEM

1 minute read

Earnings

Earnings Outlook For Aurinia Pharmaceuticals

By Benzinga Insights

February 14, 4:01 PM

Aurinia Pharmaceuticals (NASDAQ:AUPH) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here’s what investors…

AUPH

1 minute read

What’s Going On With Aurinia Pharmaceuticals Stock?

By Erica Kollmann

January 5, 11:56 AM

Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To Know:

AUPH

1 minute read

What’s Going On With Aurinia Pharmaceuticals Stock?

By Adam Eckert

November 20, 1:38 PM

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week.

AUPH

1 minute read

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan

By Benzinga Newsdesk

November 13, 7:01 AM

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the

AUPH

6 minute read

Aurinia Presents Breadth Of Data From AURORA Clinical Program Underscoring Value Of LUPKYNI For Patients With Lupus Nephritis At ACR 2023

By Benzinga Newsdesk

November 7, 11:35 AM

A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen

AUPH

5 minute read

Aurinia Presents Breadth Of Data At ASN 2023 Demonstrating Clinical Importance Of LUPKYNIS For Managing Lupus Nephritis

By Benzinga Newsdesk

November 2, 6:02 PM

Patients treated with LUPKYNISⓇ in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury.A propensity analysis of AURORA 1 suggested

AUPH